Leg ulcers associated with tyrosine kinase inhibitors of vascular endothelial growth factor receptors
- 17 November 2025
- journal article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (6)
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- A case of multiple hepatocellular carcinoma experiencing complete responses to sorafenib and atezolizumab–bevacizumab and developing severe, refractory venous congestive cutaneous ulcers on either regimenClinical Journal of Gastroenterology, 2023
- Leg ulcers associated with cutaneous vascular degeneration in a patient receiving pazopanib chemotherapyEuropean Journal Of Dermatology, 2017
- Ulcères des membres inférieurs développés sous inhibiteurs de tyrosine kinase (sunitinib, nilotinib)Annales de Dermatologie et de Vénéréologie, 2017
- Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literatureSupportive Care in Cancer, 2014
- Effect of Tyrosine Kinase Inhibitors on Wound Healing and Tissue Repair: Implications for Surgery in Cancer PatientsDrug Safety, 2014
- Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance databaseBritish Journal of Clinical Pharmacology, 2011
- Lower Limbs Erosions Induced by SunitinibActa Dermato-Venereologica, 2011
- Pyoderma Gangrenosum With the Use of SunitinibJournal of Clinical Oncology, 2011
- Ulcérations des membres inférieurs sous sunitinibAnnales de Dermatologie et de Vénéréologie, 2010
- VigiBase, the WHO Global ICSR Database System: Basic FactsDrug Information Journal, 2008